As you will be aware the Department for Health and Social Care has asked NICE to conduct an appraisal of talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy.
This appraisal has been rescheduled to allow the company to include important data to be presented in their submission. This delay means that this appraisal will be removed from NICE’s reporting targets for timeliness. In addition, as the delay will mean a NICE recommendation will not be available at the point of marketing authorisation, the company accepts that this drug will consequently not be eligible to receive interim CDF funding from the date of marketing authorisation.
It is anticipated that the appraisal will begin in late January 2020 when we will write to you about how you can get involved.